Holmium-166 Radioembolization: Current Status and Future Prospective
Martina Stella, Arthur J. A. T. Braat, Rob van Rooij, Hugo W. A. M. de Jong, Marnix G. E. H. Lam
Abstract
Abstract Since its first suggestion as possible option for liver radioembolization treatment, the therapeutic isotope holmium-166 ( 166 Ho) caught the experts’ attention due to its imaging possibilities. Being not only a beta, but also a gamma emitter and a lanthanide, 166 Ho can be imaged using single-photon emission computed tomography and magnetic resonance imaging, respectively. Another advantage of 166 Ho is the possibility to perform the scout and treatment procedure with the same particle. This prospect paves the way to an individualized treatment procedure, gaining more control over dosimetry-based patient selection and treatment planning. In this review, an overview on 166 Ho liver radioembolization will be presented. The current clinical workflow, together with the most relevant clinical findings and the future prospective will be provided.